Cue Biopharma (NASDAQ:CUE) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Cue Biopharma (NASDAQ:CUE) from a hold rating to a sell rating in a research note published on Sunday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cue Biopharma in a report on Thursday, August 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Cue Biopharma Price Performance

CUE stock opened at $26.76 on Friday. The firm has a market cap of $194.28 million, a price-to-earnings ratio of -0.99 and a beta of 2.47. Cue Biopharma has a 1-year low of $4.97 and a 1-year high of $45.50. The firm has a fifty day moving average price of $29.29 and a two-hundred day moving average price of $131.81.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The business had revenue of $7.88 million during the quarter, compared to analyst estimates of $3.00 million. Cue Biopharma had a negative net margin of 435.83% and a negative return on equity of 620.06%.

Insider Activity at Cue Biopharma

In related news, CEO Shao-Lee Lin sold 40,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $27.10, for a total transaction of $1,084,000.00. Following the completion of the transaction, the chief executive officer directly owned 724,253 shares in the company, valued at $19,627,256.30. This represents a 5.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Michael Vincent Meluzio sold 5,628 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $30.09, for a total transaction of $169,346.52. Following the transaction, the vice president owned 48,961 shares in the company, valued at approximately $1,473,236.49. The trade was a 10.31% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 72,715 shares of company stock worth $2,041,555 in the last ninety days. 14.56% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Texas Capital Bank Wealth Management Services Inc acquired a new stake in Cue Biopharma during the second quarter worth $722,000. Persistent Asset Partners Ltd acquired a new position in shares of Cue Biopharma in the 2nd quarter valued at $389,000. GC Wealth Management RIA LLC lifted its holdings in shares of Cue Biopharma by 35.0% during the 4th quarter. GC Wealth Management RIA LLC now owns 4,631,644 shares of the company’s stock worth $1,415,000 after acquiring an additional 1,200,000 shares during the period. Bank of America Corp DE bought a new position in shares of Cue Biopharma during the 2nd quarter worth about $219,000. Finally, BlackRock Inc. acquired a new stake in shares of Cue Biopharma during the 2nd quarter valued at about $1,824,000. 35.04% of the stock is currently owned by institutional investors and hedge funds.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.